ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Overview
NASDAQ:ALXO - US00166B1052 - Common Stock
ALXO Key Statistics, Chart & Performance
The current stock price of ALXO is 1.17 USD. In the past month the price increased by 125.83%. In the past year, price decreased by -49.57%.
ALXO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-07-17. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. The company focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. The company also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Company Info
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 49
Phone: 16504667125
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What is the stock price of ALX ONCOLOGY HOLDINGS INC today?
The current stock price of ALXO is 1.17 USD. The price increased by 2.63% in the last trading session.
What is the ticker symbol for ALX ONCOLOGY HOLDINGS INC stock?
The exchange symbol of ALX ONCOLOGY HOLDINGS INC is ALXO and it is listed on the Nasdaq exchange.
On which exchange is ALXO stock listed?
ALXO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALX ONCOLOGY HOLDINGS INC stock?
12 analysts have analysed ALXO and the average price target is 2.3 USD. This implies a price increase of 96.15% is expected in the next year compared to the current price of 1.17. Check the ALX ONCOLOGY HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALX ONCOLOGY HOLDINGS INC worth?
ALX ONCOLOGY HOLDINGS INC (ALXO) has a market capitalization of 62.65M USD. This makes ALXO a Micro Cap stock.
How many employees does ALX ONCOLOGY HOLDINGS INC have?
ALX ONCOLOGY HOLDINGS INC (ALXO) currently has 49 employees.
What are the support and resistance levels for ALX ONCOLOGY HOLDINGS INC (ALXO) stock?
ALX ONCOLOGY HOLDINGS INC (ALXO) has a support level at 0.61 and a resistance level at 1.18. Check the full technical report for a detailed analysis of ALXO support and resistance levels.
Should I buy ALX ONCOLOGY HOLDINGS INC (ALXO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALXO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALXO, evaluating the profitability, health, valuation and growth aspects
- ALX ONCOLOGY HOLDINGS INC (ALXO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALX ONCOLOGY HOLDINGS INC (ALXO) Sales and EPS estimates to see what analysts future expectations are.
- ALX ONCOLOGY HOLDINGS INC (ALXO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALX ONCOLOGY HOLDINGS INC (ALXO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Chart to make your own analysis
- ALX ONCOLOGY HOLDINGS INC (ALXO) Latest news and press-releases to stay up to date.
Does ALX ONCOLOGY HOLDINGS INC (ALXO) stock pay dividends?
ALXO does not pay a dividend.
When does ALX ONCOLOGY HOLDINGS INC (ALXO) report earnings?
ALX ONCOLOGY HOLDINGS INC (ALXO) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of ALX ONCOLOGY HOLDINGS INC (ALXO)?
ALX ONCOLOGY HOLDINGS INC (ALXO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.14).
What is the Short Interest ratio of ALX ONCOLOGY HOLDINGS INC (ALXO) stock?
The outstanding short interest for ALX ONCOLOGY HOLDINGS INC (ALXO) is 10.52% of its float. Check the ownership tab for more information on the ALXO short interest.
ALXO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is one of the better performing stocks in the market, outperforming 91.14% of all stocks.
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. ALXO may be in some trouble as it scores bad on both profitability and health.
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -2.14. The EPS increased by 41.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.3% | ||
| ROE | -180.97% | ||
| Debt/Equity | 0.13 |
ALXO Forecast & Estimates
12 analysts have analysed ALXO and the average price target is 2.3 USD. This implies a price increase of 96.15% is expected in the next year compared to the current price of 1.17.